ReviewBritish journal of pharmacology2019
Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.
Review in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660083 (Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases.Frontiers in oncology · 2026Trial
- NOS2 and COX2 impact the spatial landscape of CD8Redox biology · 2026Review
- Serum fatty acid profiles across clinicopathologic heterogeneity in breast cancer: an exploratory study.Therapeutic advances in medical oncology · 2026Article
- Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.JCI insight · 2025Article
- Target and Gene-Based Therapeutic Strategies against Pancreatic Cancer: Current and Future Prospects.Current gene therapy · 2025Review
- Adjuvant COX inhibition augments STING signaling and cytolytic T cell infiltration in irradiated 4T1 tumors.JCI insight · 2024Article
- Single nucleotide polymorphisms in the development of osteomyelitis and prosthetic joint infection: a narrative review.Frontiers in immunology · 2024Review
- Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.bioRxiv : the preprint server for biology · 2023Article
- Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.The Journal of clinical investigation · 2023Article
- Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment.Drug delivery and translational research · 2023Review
- Targeting Nitric Oxide: Say NO to Metastasis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Interferon-gamma is quintessential for NOS2 and COX2 expression in ERCell death & disease · 2023Article
- New nitrosyl ruthenium complexes with combined activities for multiple cardiovascular disorders.Dalton transactions (Cambridge, England : 2003) · 2023Article
- Article
- Ferroptosis regulator NOS2 is closely associated with the prognosis and cell malignant behaviors of hepatoblastoma: a bioinformatic andFrontiers in oncology · 2023Article
- Development of a prognostic model based on ferroptosis-related genes for colorectal cancer patients and exploration of the biological functions of NOS2Frontiers in oncology · 2023Article
- The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease.Critical reviews in oncogenesis · 2023Review
- Review
- The Complexity of Sesquiterpene Chemistry Dictates Its Pleiotropic Biologic Effects on Inflammation.Molecules (Basel, Switzerland) · 2022Review
- Chemiluminescence Measurement of Reactive Sulfur and Nitrogen Species.Antioxidants & redox signaling · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Recent findings suggest that co-expression of NOS2 and COX2 is a strong prognostic indicator in triple-negative breast cancer patients. These two key inflammation-associated enzymes are responsible for the biosynthesis of NO and PGE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.